Fibromyalgia Syndrome and Disease Activity in Systemic Lupus Erythematosus

Abstract

To study the effect of fibromyalgia syndrome (FS) on the expression of systemic lupus erythematosus (SLE) and on the measurement of disease activity, we performed a cross-sectional study of subjects with SLE. Eighty-seven subjects were studied and 22 (25.3%), all female, had FS (Yunus' criteria). Disease activity and organ system involvement were assessed using the systemic lupus activity measure (SLAM) and using 10 cm visual analogue scales (VAS) completed by both physician and patient. No significant difference between FS and non-FS groups in the objective measurement of disease activity was present, median (range) SLAM scores being 5 (0-18) and 6 (0-24), respectively (NS). Similarly, expression of SLE, as measured by the prevalence of specific organ system involvement, was similar in the two groups. In contrast the prevalence of glucocorticoid use, antibodies to DSDNA and fulfilling four ACR criteria was higher in the non-FS group. The rating of SLE disease activity was affected by concomitant FS. Physician and patient disease activity VAS correlated significantly with SLAM scores in non-FS subjects (P < 0.001, Spearman analysis), whereas in FS subjects, neither physician nor patient VAS correlated with SLAM scores. We conclude that FS is prevalent in individuals with SLE and does not affect disease expression but may interfere with the rating of disease activity.

Keywords

Systemic lupus erythematosus Fibromyalgia syndrome Disease activity

Get full access to this article

View all access options for this article.

References

Rothfield N. Systemic lupus erythematosus: clinical aspects and treatment. In: Arthritis and Allied Conditions. McCarty DJ (ed.). Philadelphia: Lea and Febiger, 1989: 1028.

Reilly PA , Littlejohn GO Peripheral arthralgic presentation of fibrositis/fibromyalgia syndrome . J Rheumatol 1992; 9: 281-3.

Wysenbeek AJ , Leibovici L. , Amit M. , Weinberger A. Disease patterns of patients with systemic lupus erythematosus as shown by application of factor analysis. J Rheumatol 1992; 19: 1096-9.

Vitali C. , Tavoni A. , Neri R. Castrogiovanni P, Pasero G, Bombardieri S. Fibromyalgia features in patients with primary Sjögren's syndrome. Evidence of a relationship with psychological depression. Scand J Rheumatol 1989 ; 18: 21-7.

Ferraccioli G. , Cavalieri F. , Salaffi F. et al. Necroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). J Rheumatol 1990; 17: 869-73.

McGregor AM Immunoendocine interactions and autoimmunity. N Engl J Med 1990; 322: 1739-41.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.

Yunus MB , Masi AT , Aldag JC Preliminary criteria for primary fibromalgia syndrome (PFS): multivariate analysis of a consecutive series of PFS, other pain patients and normal subjects . Clin Exp Rheumatol 1989; 7: 63-9.

Liang MH , Socher SA , Larson MG , Schur PH Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-18.

10.

McNeilage LJ , Youngchaiyud U. , Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma . Arthritis Rheum 1989; 32: 54-60.

11.

Hartz A. , Kirchdoerfer E. Undetected fibrositis in primary care practice. J Fam Pract 1987; 25: 365-9.

12.

Lindal E. , Stefansson JG , Steinsson K. Pain and pain problems among subjects with systemic lupus erythematosus in Iceland. Scand J Rheumatol 1993; 22: 10-13.

13.

Morand EF , Goulding NJ Glucocorticoids in rheumatoid arthritis: mediators and mechanisms . Br J Rheumatol 1993 ; 32: 816-19.

14.

Wilder RL , Sternberg EM Neuroendocrine hormonal features in rheumatoid arthritis and related conditions . Curr Opin Rheumatol 1990; 2: 436-40.

15.

McMurray RW , Allen SH , Braun A. Walker SE Longstanding hyperprolactinaemia in systemic lupus erythematosus. Arthritis Rheum 1992; 35 (Suppl.): S168 (abstract).

16.

Russell U. Neurohormonal aspects of fibromyalgia syndrome. Rheum Dis Clin Nth Am 1989; 15: 149-68.

17.

Vaeroy H. , Helle R. , Forre O. et al. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 21-6.

18.

Littlejohn GO , Weinstein C. , Helme RD Increased neurogenic inflammation in fibrositis syndrome. J Rheumatol 1987 ; 14: 1022.

19.

Payan DG , Brewster DR , Goetzel EJ Specific stimulation of human T lymphocytes by substance P. J Immunol 1983; 131: 1613-15.

20.

Hartung HP , Toyka K. Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol 1983 ; 89: 301-5.

21.

Smythe HA , Lee D. , Rush P. , Buskila D. Tender shins and steroid therapy. J Rheumatol 1991 ; 18: 1568-72.

22.

Granges G. , Littlejohn GO Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes and in patients with fibromyalgia. Arthritis Rheum 1993; 36: 642-6.

23.

Wolfe F. , Smythe HA , Yunus MB et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990; 33: 160-72.

24.

Bennett RM , Clark SR , Campbell SM et al. Symptoms of Raynaud's phenomenon in patients with fibromyalgia . Arthritis Rheum 1991; 34: 264-9.

25.

Guzman J. , Cardiel MH , Arce-salinas A. , Sanchez-Guerrero J. , Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-8.

26.

Symmons Dpm , Coppock JS , Bacon PA et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988; 69: 927-37.

27.

Lockshin MD , Reinitz E. , Druzin ML , Murrman M. , Estes D. Lupus pregnancy: case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy . Am J Med 1984; 77: 893-8.

28.

Morimoto C. , Sano H. , Abe T. , Homma M. , Steinberg AD Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/anti-DNA antibody immune complexes. J Immunol 1982; 139: 1960-5.